TYME News and Press, Tyme Technologies Inc. From 01/26/22

-- SM-88 with MPS arm of Phase 2/3 platform trial in metastatic pancreatic cancer discontinued for futility on primary endpoint of overall survival – TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer meta...

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that Richie Cunningham, Chief Executive Officer, and Jonathan Eckard, Chief Business Officer, will present at the...

Tyme Technologies (NASDAQ:TYME) has received a non-compliance notice from The Nasdaq Stock Market. The company failed to comply with the minimum bid price requirement for continued inclusion on the exchange under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). It now has 180...

-- TYME-19 demonstrated an antiviral effect against SARS CoV-2 in human lung epithelial cells, a model frequently used for drug screening for antiviral efficacy -- -- Completed toxicity studies with TYME-19 that are expected to enable an Investigational New Drug (IND) application an...

Penny Stocks Insiders Decided To Buy In December 2021 Penny stocks are a great way to make money in the stock market without waiting years for a return. Even though they’ve got more risk to account for, the way traders can leverage smaller sums of capital to reap hefty gains isn&...

-- Oral SM-88 is an investigational cancer metabolism-based therapy that has demonstrated clinical responses across 15 different types of solid tumors and hematologic cancers – -- Prestigious conference features new, innovative findings in gastrointestinal cancer tr...

Tyme Technologies recently reported their Q2 earnings that revealed the company only burned roughly $5M in cash with about $97M left in the bank. The small-cap sell-off has pushed the share price to fresh 52-week lows. I believe TYME has an incredible risk-reward at these prices. ...

Tyme Technologies, Inc. (TYME) Q2 2021 Earnings Conference Call November 8, 2021, 8:30 AM ET Company Participants Richie Cunningham – Chief Executive Officer Lisa Wilson – Investor Relations Frank Porfido – Chief Financial Officer Dr. Yan Von Tornaut – Acting Chief...

Tyme Technologies (NASDAQ:TYME): Q2 GAAP EPS of -$0.03. As of the quarter ended September 30, 2021, the Company had approximately $96.6M in cash and marketable securities, compared to $101.5M as of the quarter ended June 30, 2021. Operational cash burn rate for the second quarter of fiscal ye...

– First patient dosed in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor – – PanCAN Precision Promise trial to add five new sites in early 202...